KEEPING UP WITH TECHNOLOGY TO CREATE CURES FOR CANCER AND ALZHEIMER’S

Normandale Partners Led ImmunoChemistry Technologies to earn ISO 9001 Certification and Stay Competitive

Sally Hed Dahlquist, owner and president of ImmunoChemistry Technologies (ICT), has positioned her firm for new opportunities and growth through a workforce development grant. Normandale secured a grant to help ICT earn its ISO 9001 certification along with other key laboratory and certification trainings.

The grant was critical because ICT needed to be able to compete against larger scale analytical labs and ISO certification would create the foundation to meet that challenge.

“Normandale played a huge role in our company becoming ISO certified. As a small company that mostly focuses on research, the ISO process would have been difficult for us to navigate. Normandale made sure we were informed and prepared to succeed every step of the way.”

– Sally Hed Dahlquist

ICT develops tools and technologies that enable biomedical researchers to discover new drugs and treatments for cancer and other diseases like Alzheimer’s, inflammation, and immune deficiencies. ICT is considered a leading supplier of apoptosis detection kits. Cited in over 2,000 scientific publications, ICTs customers have included Harvard, Yale, University of Minnesota, as well as cancer research centers such as Fred Hutchinson Cancer Research Center, Moffitt Cancer Center, MD Anderson Cancer Center, and research institutions such as the National Institute of Health (NIH).

While Sally’s company still meets the definition of a small business (10 employees), her employees are now prepared to meet their goals for future expansion and growth.